

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : El-Naggar et al.

Examiner: B. Kwon

FAX RECEIVED  
JUN 27 2003  
CANCELLATION  
PETITIONS OFFICE

Appl. No. : 09/943,048

Art Unit: 1614

FAX RECEIVED

JUN 30 2003

Filed : August 30, 2001

PETITIONS OFFICE

For : Treatment of Inflammatory, Cancer, and Thrombosis Disorders

Commissioner of Patents  
And Trademarks  
Washington, D.C. 20231

Sir:

This Amendment responds to the Office Action mailed April 10, 2002. A request for three months extension of time accompanies this Amendment. Please amend the application as follows:

Response to Restriction Requirement

Applicants affirm, with traverse, election of group III (Claim 4) in response to a restriction requirement.

AmendmentIN THE CLAIMS:

Please amend claims 1 and 5 as follows:

- B1
1. (Amended) A method of treating inflammatory disorders in a mammal comprising administering to said mammal a combination of: (i) a standard therapeutic dose of a COX2 inhibitor selected from the group consisting of [(i)] celecoxib [(CelebrexR) [A,]] and rofecoxib [(VioxxR) [B], and other specific COX2 inhibitors [C]], (ii) low dose aspirin in the amount of [70-85 mg], and (iii) antioxidant flavanoids, flavonoids or isoflavones.
  

B2

  5. (Amended) The method of claim 1, wherein the [COX2 inhibitors] compound [A], compound [B] or compound [C] and low dose aspirin [of 70-85 mg] is in an enteric coated formulation. [This preferred enteric-coated formulation should allow for improved efficacy and safety.]